3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
38
Colorectal Neoplasms
18
Stomach Neoplasms
7
Biliary Tract Neoplasms
5
Rectal Neoplasms
3
Neoplasm Metastasis
3
Cholangiocarcinoma
3
Neoplasms
2
Metastatic Pancreatic Adenocarcinoma
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Wilms Tumor
1
Weight Loss
1
Triple Negative Breast Neoplasms
1
Small Bowel Adenocarcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Rectal Cancer Patients
1
Pseudomyxoma Peritonei
1
Peritoneal Neoplasms
1
Pancreatic cancer, adult
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Diseases
1
Pancreatic Cancer Non-resectable
1
Pancreatic Cancer Metastatic to Liver
1
Pancreatic Adenocarcinoma
1
PDAC - Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Interventions
Gemcitabine
40
Cisplatin
24
Capecitabine
21
Fluorouracil
19
Oxaliplatin
17
Leucovorin
14
pembrolizumab
9
Irinotecan
8
Radiotherapy
7
Erlotinib Hydrochloride
7
durvalumab
6
Sorafenib
4
Photochemotherapy
4
Magnetic Resonance Spectroscopy
4
Carboplatin
4
trametinib
3
Trastuzumab
3
Radiofrequency Ablation
3
Long-Term Synaptic Depression
3
Interleukin-12 Subunit p35
3
Filgrastim
3
Drug Therapy
3
Dihematoporphyrin Ether
3
Dexamethasone
3
Cholangiopancreatography, Endoscopic Retrograde
3
Chemotherapy, Adjuvant
3
trifluridine tipiracil drug combination
2
tivozanib
2
tislelizumab
2
spartalizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
irinotecan sucrosofate
×
Gastrointestinal
×
Clear all
NCT05277766
2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1
Recruiting
45 enrolled